Status:
UNKNOWN
Treatment of Hepatocellular Carcinoma With Radiofrequency Ablation (RFA) Associated With Postoperative TACE
Lead Sponsor:
Southwest Hospital, China
Collaborating Sponsors:
Agency for Science, Technology and Research
Conditions:
Cancer of Liver
Eligibility:
All Genders
18-75 years
Phase:
NA
Brief Summary
A RCT was conducted to elucidate whether the treatment outcome of HCC could be improved by RFA associated with postoperative TACE.
Detailed Description
A randomized study was conducted to elucidate whether the outcome of hepatocellular carcinoma could be improved by radiofrequency ablation associated with postoperative transhepatic arterial chemoembo...
Eligibility Criteria
Inclusion
- patients with hepatocellular,confirmed by pathological examination
- patients with a live function test showed Child A or B
- Indocyanine green test showed less than 30％ after 15min,and the patients showed a tolerance of RFA and TACE
- Tumor stage is early period(according to Milan Standard),that is,the diameter of single node should be less than 5cm；the node of tumor should be less than 3 and the diameter less than 3cm.
- without metastasis in lymphnode or other organs
- written consent inform assigned
Exclusion
- preoperative examination showed malignant thrombosis in the first class branch of portal vein or hepatic vein or vena cava
- metastatic cancer of liver
- patients with a poor tolerance of RFA and TACE
- patients received other therapies.
Key Trial Info
Start Date :
December 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 1 2018
Estimated Enrollment :
140 Patients enrolled
Trial Details
Trial ID
NCT00730860
Start Date
December 1 2009
End Date
June 1 2018
Last Update
March 28 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Institute of hepatobiliary surgery
Chongqing, Chongqing Municipality, China, 400038